Literature DB >> 1282160

Treatment of metastatic testicular tumours with bleomycin, etoposide, cisplatin and vincristine (BEPV).

B A Price1, N H Peters.   

Abstract

Between August 1983 and December 1988, 47 patients with metastatic testicular tumours (44 non-seminomatous, three seminomas) were treated with two to six courses of bleomycin, etoposide, cisplatin and vincristine (BEPV). Five stage I tumours were included, three because of raised tumour markers following orchidectomy, one with vascular invasion of spermatic cord vessels and the other with both these features. Forty-four patients (93.6%) are alive and disease free 12-75 months (median 39 months) after completion of BEPV. Further treatment was necessary in 12 of the survivors. Eight had residual disease excised, one of whom received radiotherapy, one additional chemotherapy and one both radiotherapy and chemotherapy. Of the remaining four, two had radiotherapy and two second line chemotherapy. Thirty-one non-seminomatous and the three seminoma patients had small volume disease and all are in complete remission. Ten of the 13 patients with bulky disease are alive. It is concluded that BEPV is a well-tolerated, effective, first line therapy for patients with metastatic testicular tumour.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282160      PMCID: PMC1293725          DOI: 10.1177/014107689208501107

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  16 in total

1.  CLINICAL EVALUATION OF VINCRISTINE (NSC-67574).

Authors:  R K SHAW; J A BRUNER
Journal:  Cancer Chemother Rep       Date:  1964-11

2.  Vinblastine in the management of testicular cancer.

Authors:  M L Samuels; C D Howe
Journal:  Cancer       Date:  1970-05       Impact factor: 6.860

3.  Epidemiology of testicular tumours.

Authors:  J A Waterhouse
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

4.  Bleomycin combination chemotherapy in the management of testicular neoplasia.

Authors:  M L Samuels; P Y Holoye; D E Johnson
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

5.  Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors.

Authors:  J N Wettlaufer; A S Feiner; W A Robinson
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

6.  Chemotherapy of disseminated testicular cancer. A random prospective study.

Authors:  L H Einhorn; S D Williams
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

7.  Combined management of malignant teratoma of the testis.

Authors:  M J Peckham; T J McElwain; A Barrett; W F Hendry
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

8.  Further advances in the management of malignant teratomas of the testis and other sites.

Authors:  E S Newlands; R H Begent; G J Rustin; D Parker; K D Bagshawe
Journal:  Lancet       Date:  1983-04-30       Impact factor: 79.321

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

10.  The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).

Authors:  M J Peckham; A Barrett; K H Liew; A Horwich; B Robinson; H J Dobbs; T J McElwain; W F Hendry
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.